Wuxi Apptec Co., Ltd. Class A · SSE:603259
Wuxi Apptec Co., Ltd. Class A — Q3 2025 Earnings Presentation
19 slides from Wuxi Apptec Co., Ltd. Class A's earnings presentation, Oct 27, 2025
Slide 1: Third Quarterly 2025 Results
WuXi AppTec Third Quarterly 2025 Results October 27, 2025 1 603259.SH / 2359.HK
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as “expects”, “plans”, “will”, “estimates”, “projects”, “intends”, or words of similar meaning. Such forward-looking statements are not his
Slide 3: Results Overview, Segment Performance, Financial Performance, Company Outlook
01 Results Overview 02 Segment Performance 03 Financial Performance 04 Company Outlook 3 Note: Unless otherwise stated, all financials disclosed in this presentation are prepared based on IFRSs. The currency is RMB. All net profit disclosed in this presentation represents net profit attributable to
Slide 4: 1. Results Overview
1. Results Overview WW totic
Slide 5: Q1-Q3 2025 Revenue & Profit Achieved Strong Growth
Q1-Q3 2025 Revenue & Profit Achieved Strong Growth; Revenue from Continuing Operations Up 22.5% YoY, and Adjusted Non-IFRS Net Profit Up 43.4% YoY Revenue Adjusted Non-IFRS Net Profit RMB billion RMB billion Adjusted Non-IFRS NPM +18.6% +22.5%1 +43.4% Revenue from Continuing Operations 26.5% 32.1% 3
Slide 6: Backlog for Continuing Operations Up 41.2% YoY
With Continuous Capacity Expansion to Better Meet Customer Demand, Backlog for Continuing Operations1 Up 41.2% YoY as of September 30, 2025 Backlog for Continuing Operations1 RMB billion +41.2% 59.88 56.69 52.16 49.06 41.32 42.40 35.28 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 6 Note:
Slide 7: Diversified Revenue Streams Across Regions
Diversified Revenue Streams of Continuing Operations from Customers Across Regions Ensure the Stability and Resilience of the Company’s Financial Performance RMB billion China Europe 5.04Bn，+0.5% 3.84Bn，+13.5% Revenue contribution: 16% Revenue contribution: 12% US 22.15Bn，+31.9% Revenue contribution
Slide 8: 2. Segment Performance
2. Segment Performance WW totic
Slide 9: WuXi Chemistry: CRDMO Business Model Drives Continuous Growth
WuXi Chemistry: CRDMO Business Model Drives Continuous Growth, Q1-Q3 2025 Revenue Up 29.3% YoY, with TIDES Revenue Up 121.1% YoY CRDMO Business Model Drives Continuous Growth Revenue & Gross Profit Margin ⚫ WuXi Chemistry Q1-Q3 revenue up 29.3% YoY to 25.98bn ⚫ With continued optimization of product
Slide 10: Small Molecule CRDMO Pipeline Efficiently Converts and Captures Molecules
WuXi Chemistry: Driven by “Follow the Molecule + Win the Molecule”, Small Molecule CRDMO Pipeline Efficiently Converts and Captures High-Quality Molecules, Delivering Sustained Growth “R” 5%↓ 430,000+ 14,751 compounds Compounds Q1-Q3 2025 Newly Added Molecules to D&M Pipeline 2,889 Preclinical & Pha
Slide 11: WuXi Testing: Drug Safety Evaluation Service & SMO Maintain Leading Positions
WuXi Testing: Drug Safety Evaluation Service & SMO Maintain Leading Positions Revenue & Gross Profit Margin Lab Testing Services ⚫ With development of differentiated capabilities and enhanced operational management, Q3 revenue of lab testing services reached 1.08bn, up 7.2% YoY RMB billion and 7.5%
Slide 12: WuXi Biology: Continues to Generate Downstream Opportunities
WuXi Biology: Continues to Generate Downstream Opportunities; In Vitro & In Vivo Business Synergies and New Modality Business Drive Growth Revenue & Gross Profit Margin ⚫ Follow the science, continuously strengthen drug discovery capabilities in emerging areas and actively grow overseas businesses.
Slide 13: 3. Financial Performance
3. Financial Performance WW totic
Slide 14: Strengthen Technological Expertise and Operating Efficiency, Enhancing Profitability
Continuously Strengthen Technological Expertise and Operating Efficiency, Leverage Management Resilience, Further Enhancing Profitability Adjusted Non-IFRS Gross Profit Adjusted Non-IFRS GPM* Adjusted Non-IFRS Net Profit Adjusted Non-IFRS NPM RMB billion RMB billion 40.3% 38.0% 38.7% 42.0% 41.6% 40.
Slide 15: Q1-Q3 2025 Operating Cash Flow Up 35.0% YoY
With Continued Business Growth, Efficient Operations and Constant Improvement of Financial Management Capabilities, Q1-Q3 2025 Operating Cash Flow Up 35.0% YoY to 10.87 Billion RMB billion Capex1 12.64 11.99 Operating Cash Flow 10.87 9.97 10.23 8.05 6.94 5.52 4.38 3.83 4.00 3.57 3.03 2.49 2020 2021
Slide 16: 4. Company Outlook
4. Company Outlook WW totic
Slide 17: Continue to Focus on CRDMO Business Model
Continue to Focus on CRDMO Business Model, and Accelerate Growth of Global Capabilities and Capacities ⚫ To further focus and strengthen our core CRDMO business and invest to accelerate growth of global capabilities and capacities, by concentrating on drug discovery, laboratory testing, process deve
Slide 18: Company Outlook
Company Outlook Focus on the CRDMO business model, striving for highly efficient & exceptional services and lean operations ("O") ⚫ Continue to focus on our unique integrated CRDMO core business, and accelerate global expansion, capacity construction and capability development ⚫ Leveraging customers
Slide 19: Company Outlook: Rewarding Shareholders
Company Outlook Remain committed to rewarding shareholders and upholding the Company's value ⚫ This year, the Company has implemented a total of RMB6.88 billion in cash dividends, share repurchases and cancellations, representing 70%+ of the Company’s net profit1 in 2024: - distributed a total of RM